Summary
The therapy of gastrointestinal cancer is currently based on the surgical removal of the primary tumor or the metastases, respectively. A major improvement of the five year survival rate or an effective cure from advanced tumors will mainly depend on adjuvant therapeutic concepts even after surgical R0-resection. Such concepts can be developed nowadays with major expectations for success based on our advanced molecular biological knowledge on (i) increased proliferation, (ii) reduced apoptosis rate, (iii) the dissemination and (iv) the mechanisms of invasive growth of malignant cells.
Key words
Schlüsselwörter
Zusammenfassung
Die Therapie gastrointestinaler Karzinome basiert derzeit in erster Linie auf der chirurgischen Entfernung des Primärtumors bzw. bereits etablierter Metastasen. Eine entscheidende Verbesserung der Fünf-Jahres-Überlebensraten bzw. eine wirkliche Heilung bei fortgeschrittenen Tumoren ist auch nach chirurgischer R0-Resektion nur dann zu erwarten, wenn rechtzeitig adjuvante Therapiekonzepte zum Einsatz kommen. Diese können heute mit großer Aussicht auf Erfolg auf der Grundlage neuer molekularbiologischer Erkenntnisse über die erhöhte Proliferation, die verringerte Apoptosefähigkeit, die Dissemination und die Mechanismen des invasiven Wachstums maligner Zellen erarbeitet werden.
Key words
Schlüsselwörter
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9: 138–141.
Hahn SA, Kern SE, Schmiegel WH (1997) Neue molekularbiologische Erkenntnisse aus der Pankreaskarzinom-Forschung. Deutsches Ärzteblatt 49: 2706–2712.
Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H (1998) Human Pancreatic Adenocarcinomas Express Fas and Fas Ligand Yet Are Resistant to Fas-mediated Apoptosis. Cancer Res 58: 1741–1749.
Herr I, Wilhelm D, Böhler T, Angel P, Detatin KM (1997) Activation of CD95 (APA-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. The EMBO J 16: 6200–6208.
Hirata H, Takahashi A, Koboyashi S, Yonehara S, Hirofumi S, Okazaki T, Yamamoto K, Sasada M (1998) Caspases Are Activated in a Branched Protease Cascade and Control Distinct Downstream Process in Fas-induced Apoptosis. J Exp Med 187: 587–600.
Brand PA, Röder C, Kornahl V, Kremer B, Kalthoff H (1997) Interleukin-1β is expressed, processed, and secreted as bioactive cytokine by pancreatic tumor cells. 28th Annual Meeting 1997 of Immunobiology 24.-27.09: 379.
Tatsuta T, Cheng J, Mountz JD (1996) Intracellular IL-β Is an Inhibitor of Fas-Mediated Apoptosis. J Immunol 3949-3957.
Schmielau J, Kalthoff H, Roeder C, Schmiegel W (1996) The Role of Cytokines in Pancreatic Cancer. Int J Pancreatol 19: 157–163.
Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation. Cell 64: 327–336.
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN (1994) Up-regulation of Cyclooxygenase 2 Gene Expression in Human Colorectal Adenomas and Adenocarcinomas. Gastroenterology 107: 1183–1188.
Müller C, Große Bockhorn A, Klusmeier S, Kiehl M, Roeder C, Kalthoff H, Koch OM (1998) Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 12: 717–723.
Mercola D, Cohen JS (1995) Antisense approaches to cancer gene therapy. Cancer Gene Therap 2: 47–59.
Fiedler A, Knorre C, Franke Y, Henne-Bruns D, Kremer B, Lüttges J, Maier M, Gerster M, Bleicher K, Bayer E, Kalthoff H (1998) Growth inhibition of pancreatic tumor cells by modified antisense oli-godeoxynucleotides. Langenbeck’s Arch Surg 383: 269–275.
Juhl H, Downing SG, Wellstein A, Czubayko F (1997) HER-2/neu Is Rate-limiting for Ovarian Cancer Growth. J Biol Chem 272: 29482–29486.
Kalthoff H, Löhr M, Röder C, Schmiegel W (1995) Pankreaskarzinom, in: Erkrankungen des exkretorischen Pankreas: 385–404. Gustav Fischer Verlag, Stuttgart.
Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, v Elsas A, Müller M, Wolff K, Eichler HG, Pehamberger H (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Medicine: 232-234.
Sandig V, Brand K, Herwig S, Bartek J, Strauss M (1997) Adenovirally transferred pl6INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Medicine 3(3): 313–319.
Freeman SM, Whartenby KA, Freeman JL, Abbout CN, Marrogi AJ (1996) In situ use of suicide genes for cancer therapy. Semin Oncol 23(1): 31–45.
Dimaio JM, Clary M, Via DMM, Coveney E, Pappas T, Lyerly K (1994) Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116(2): 205–213.
Schott A, Vogel I, Krueger U, Kalthoff H, Schreiber H-W, Schmiegel W, Henne-Bruns D, Kremer B, Juhl H (1998) Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surgery 227(3): 372–379.
Soeth E, Vogel I, Röder C, Juhl H, Marxsen J, Krüger U, Henne-Bruns D, Kremer B, Kalthoff H (1997) Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res 57: 3106–3110.
Rietmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, et al. (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German cancer aid 17-1A Study group. Lancet 343(8907): 1177–1183.
Schmiegel W, Schmielau J, Henne-Bruns D, Juhl H, Röder C, Buggisch P, Onur A, Kremer B, Kalthoff H, Jensen E (1997) Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc Natl Acad Sci USA 94: 12622–12626.
Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650–1659.
Fujimoto J, Hori M, Ichigo S, Hirose R, Sakaguchi H, Tamaya T (1997) Plausible novel therapeutic strategy of uterine endometrical cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470). Cancer Lett 113(1–2): 187–194.
O’Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, Flynn E, Birkhead J, Olsen B, Folkman J (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277–285.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kalthoff, H., Henne-Bruns, D. (1998). Synopsis moderner Tumortherapie mit molekularbiologischen Verfahren. In: Hartel, W. (eds) Vielfalt und Einheit der Chirurgie Humanität und Wissenschaft. Langenbecks Archiv für Chirurgie, vol 1998. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45774-6_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-45774-6_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-65144-4
Online ISBN: 978-3-642-45774-6
eBook Packages: Springer Book Archive